Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Conference Call Transcript

AI summary - Semaglutide API scale-up batch showed impurity out of specification, requiring process revalidation - Commercial supply halted until validation completes, expected by late September; supply to resume October-November - No impact on existing market supplies or patient safety; no recall needed for marketed batches - Backup API supplier qualification underway, but pre-approval supplement will take about a year - Demand remains strong; 6-7 million pens supply targeted between Q3 and Q4 FY27 - Potential inventory write-down at OneSource due to halted batches - No penalties expected for supply delays; long-term partnership with OneSource maintained